印度药店公科委员会(Pharma copoeia Commission)通过新的Nagaland伙伴关系加强了东北部药店的监管,加强了药物安全和报告。 India’s Pharmacopoeia Commission strengthened Northeast pharmacovigilance via new Nagaland partnerships, boosting drug safety and reporting.

2025年12月26日, 联合卫生部长纳达(JP Nadda)检讨了印度药店委员会的进展, Union Health Minister JP Nadda reviewed the Indian Pharmacopoeia Commission’s progress on December 26, 2025, highlighting improvements in medicine quality, safety, and regulatory standards. 以加济巴德为基地的国际药委会与纳加兰各机构签署了三项新备忘录,以加强药剂监督、扩大反毒反应报告,并通过印度国家配方促进安全药品使用,这是印度在东北地区首次合作的标志。 The IPC, based in Ghaziabad, signed three new memoranda with Nagaland agencies to strengthen pharmacovigilance, expand adverse drug reaction reporting, and promote safe medicine use through the National Formulary of India—marking its first collaboration in India’s Northeast. 在9月发起全国药物警惕周之后,鼓励以数字方式报告保健提供者和病人的负面反应,支持印度争取科学自力更生和全球药品信誉的动力。 This follows the September launch of National Pharmacovigilance Week, which encouraged digital reporting of adverse reactions by healthcare providers and patients, supporting India’s push for scientific self-reliance and global pharmaceutical credibility.